Clinical Trial Update: POC Study in Partially Responsive Generalized Anxiety Disorder [Phase 2]

View source ↗

Summary

Pfizer conducted a Phase 2 proof-of-concept study in partially responsive Generalized Anxiety Disorder. The study was terminated and results were posted on 2016…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Snippet

Sponsor: Pfizer | Conditions: Generalized Anxiety Disorder | Phase 2 | Status: TERMINATED | Results posted: 2016-11-15